|Other names||Daxi, daxibotulinumtoxinA-lanm|
|Drug class||Botulinum toxin|
|Main uses||Wrinkles between the eyebrows|
|Side effects||Headache, eyelid dropping, trouble moving the face, breathing problems|
|Duration of action||Up to 6 months|
DaxibotulinumtoxinA, sold under the brand name Daxxify, is a medication used to improvement the appearance of wrinkles found between the eyebrows. It may also be given for cervical dystonia. It is given by injection into muscle. Effects may last for up to 6 months.
Common side effects include headache, eyelid dropping, and trouble moving the face. Other side effects may include swallowing or breathing problems. It is a botulinum toxin A which inhibits acetylcholine release and is a neuromuscular blocking agent.
- "Daxxify- botulinum toxin type a injection, powder, lyophilized, for solution". DailyMed. 19 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
- Solish, N; Carruthers, J; Kaufman, J; Rubio, RG; Gross, TM; Gallagher, CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.". Drugs. 81 (18): 2091–2101. doi:10.1007/s40265-021-01631-w. PMID 34787840.
- "U.S. FDA declines to approve Revance's frown-line treatment". Reuters. 15 October 2021. Archived from the original on 17 January 2022. Retrieved 13 December 2022.
- F.D.A. OKs Daxxify, an Anti-Wrinkle Drug and Botox Competitor Archived 2022-10-03 at the Wayback Machine
- Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, et al. (January 2020). "DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)". Plastic and Reconstructive Surgery. 145 (1): 45–58. doi:10.1097/PRS.0000000000006327. PMC 6940025. PMID 31609882.
- Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A". Drugs. 81 (18): 2091–2101. doi:10.1007/s40265-021-01631-w. PMC 8648634. PMID 34787840.